Date  |
|
| Apr 5, 2021 |
9 Meters Biopharma Announces Closing of Offering of Common Stock |
| Apr 12, 2021 |
9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study |
| Apr 19, 2021 |
9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome |
| Apr 21, 2021 |
9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit |
| May 13, 2021 |
9 Meters Biopharma Provides Business Update and Reports Financial Results for the First Quarter 2021 |
| May 17, 2021 |
9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome |
| May 18, 2021 |
9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit |
| May 18, 2021 |
CORRECTION 9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit |
| May 26, 2021 |
9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children (MIS-C) resulting from COVID-19 Infection |
| Jun 1, 2021 |
9 Meters Biopharma, Inc. to Present at the Jefferies Virtual Healthcare Conference |